Pathophysiology of tardive dyskinesia

Area of Science:

• Neuroscience
• Pharmacology
• Movement Disorders

Background:

• Tardive dyskinesia (TD) is a persistent neurological disorder characterized by involuntary movements.
• Animal models are crucial for understanding the underlying mechanisms of TD.
• Neuroleptic medications are known to induce or exacerbate TD.

Purpose of the Study:

• To investigate the neurochemical changes associated with persisting tardive dyskinesia in animal models.
• To explore the role of GABAergic and dopaminergic systems in the pathophysiology of TD.

Main Methods:

• Development of animal models of tardive dyskinesia in rats and monkeys.
• Chronic administration of neuroleptics to induce dyskinetic and non-dyskinetic phenotypes.
• Biochemical analysis of glutamic acid decarboxylase (GAD) and GABA levels in specific brain regions (substantia nigra, medial globus pallidus, subthalamic nucleus).
• Assessment of striatal dopamine turnover in dyskinetic monkeys post-discontinuation of neuroleptics.

Main Results:

• Dyskinetic animals exhibited significant decreases in GAD and GABA in the substantia nigra, medial globus pallidus, and subthalamic nucleus compared to non-dyskinetic controls.
• These neurochemical alterations persisted for at least 2 months after neuroleptic discontinuation.
• Dyskinetic monkeys showed reduced striatal dopamine turnover 2 months after neuroleptic withdrawal.

Conclusions:

• Reduced GABAergic function in the substantia nigra is implicated in the pathophysiology of tardive dyskinesia.
• The findings from animal models provide insights into the long-term neurochemical consequences of neuroleptic treatment.
• Further research into GABAergic pathways may offer therapeutic targets for tardive dyskinesia.